These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27017616)

  • 21. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
    Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-based simulation to support the extended dosing regimens of atezolizumab.
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
    Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
    Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
    Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
    Noh YH; Lim HS; Jung JA; Song TH; Bae KS
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
    Lu JF; Bruno R; Eppler S; Novotny W; Lum B; Gaudreault J
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):779-86. PubMed ID: 18205003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.